L
Lys Therapeutics
Innovative biotherapies targeting neurological diseases with a focus on stroke and multiple sclerosis
About Lys Therapeutics
Lys Therapeutics is a pioneering biotech startup focused on developing innovative biotherapies for neurological diseases. The company has garnered significant attention, including winning the Grand Prize at the i-Lab innovation competition, which underscores its potential in the biotech industry. Lys Therapeutics primarily targets conditions like stroke, multiple sclerosis, and other neurodegenerative disorders. These diseases are characterized by issues such as neuroinflammation (inflammation of the nervous tissue) and excitotoxicity (nerve cell damage due to excessive stimulation).
Read full description
The company operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources. Lys Therapeutics collaborates with prestigious institutions like Inserm Transfert, a French public research organization, to advance its research and development efforts. This partnership focuses on creating treatments that can improve the permeability of the blood-brain barrier, a critical factor in treating neurological conditions.
Lys Therapeutics' business model revolves around the research, development, and eventual commercialization of its drug candidates. The company invests heavily in scientific research to develop first-in-class (the first of its kind) therapies. Revenue generation is expected to come from the successful commercialization of these therapies, either through direct sales or through licensing agreements with larger pharmaceutical companies.
The company serves a specialized client base, including healthcare providers, hospitals, and research institutions focused on treating neurological diseases. By addressing unmet medical needs in this niche market, Lys Therapeutics aims to establish itself as a leader in the biopharmaceutical industry.
At a glance
- Founded
- 2021
- Headquarters
- Caen, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
HTH
Michael J. Fox Foundation for Parkinson's Research
Bpifrance
France 2030
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lys Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lys Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.